Michael Chu


Faculty of Medicine & Dentistry - Medicine Dept
(780) 432-8757


Area of Study / Keywords


Dr. Michael Chu is a clinician scientist at the Cross Cancer Institute. He completed his medical training including General Internal Medicine residency and Medical Oncology fellowship at the University of Alberta. Dr. Chu was then awarded a Leukemia and Lymphoma Society fellowship for a combined clinical and research fellowship at Stanford University. Upon returning to Edmonton, his clinical focus includes lymphoma, myeloma, and central nervous system malignancies. Academically, his research focuses on basic and translational cancer research with an emphasis on immune therapy (including monoclonal antibodies and cellular therapy). He also has a wide range of clinical research where he serves as principal investigator and sub-principal investigator on multiple phase I, II, and III clinical trials. Dr. Chu is actively involved in trainee education particularly with the local Medical Oncology fellows providing both didactic and bedside teaching. When not working hard at the Cross Cancer Institute, Dr. Chu is also a loving husband and father while maintaining his interests in various hobbies including basketball, photography, and piano.


Areas of research include the following: cancer biology, cellular therapy, therapeutic antibodies, minimal residual disease, stem cell transplantation, and hematologic cancers

Featured Publications

Katz D.A., Morris J.D., Chu M.P., David K.A., Thieblemont C., Morley N.J., Khan S.S., Viardot A., Martín García-Sancho A., Rodríguez-García G., Bastos-Oreiro M., Lee S.T., Kormany W., Chen Y., Wong H.L., Anderson A.A., Katlinskaya Y., Avilion A.A., Dai T., González-Barca E.

Leukemia and Lymphoma. 2022 May; 10.1080/10428194.2022.2064981

Sangha R., Davies N.M., Namdar A., Chu M., Spratlin J., Beauchamp E., Berthiaume L.G., Mackey J.R.

Current Oncology. 2022 March; 29 (3) 10.3390/curroncol29030158

Elranatamab, a BCMA targeted T-cell redirecting immunotherapy, for patients with relapsed or refractory multiple myeloma

J Clin Oncol 2022. 2022 January;

Updated results from the ongoing phase 1 study of elranatamab, a BCMA targeted T-cell redirecting immunotherapy, for patients with relapsed or refractory multiple myeloma

European Hematology Association (EHA) Congress 2022. 2022 January;

Menze L., Duarte P.A., Haddon L., Chu M., Chen J.

ACS Nano. 2021 September; 16 (1) 10.1021/acsnano.1c05668

Efficacy and safety of elranatamab (PF-06863135), a B-cell Maturation Antigen (BCMA)-CD3 Bispecific Antibody, in patients with relapsed/refractory Multiple Myeloma (MM)

American Society of Clinical Oncology Annual Meeting. 2021 June;

CLINICAL NUTRITION. 2021 April; 42 (4):348-53 https://doi.org/10.1016/j.clnesp.2021.01.009

Hu X., Wang J., Chu M., Liu Y., Wang Z.w., Zhu X.

Molecular Therapy. 2021 January; 29 (3):908-919 10.1016/j.ymthe.2020.12.032

2. Preliminary Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Subcutaneously (SC) administered PF-0683135, a B-cell Maturation Antigen (BCMA)-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Blood (American Society of Hematology Annual Meeting 2020). 2020 December;